ERNA compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ERNAErnexa Therapeutics Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ERNAErnexa Therapeutics Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ERNAErnexa Therapeutics Inc.

1.95▼−3.47%· post 1.94

Mkt cap$3.3MRevenue$1,000Q4 FY24Revenue$582,000FY24

LLYELI Lilly & Co

1,417.89▲+0.60%· post 1,419.27

ClosedNov 4 '26

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 4 '26

ERNAErnexa Therapeutics Inc.

LLYELI Lilly & Co

1.95▼−3.47%post 1.94

Price

1,417.89▲+0.60%post 1,419.27

$3.3M

Mkt cap

$1.3T

Q4 FY24$1,000

Revenue

$24.4BQ3 FY26

FY24$582,000

Revenue

$65.2BFY25

ERNA1.95▼−3.47%vsLLY1,417.89▲+0.60%ClosedNov 4 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ERNA: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ERNA 1

—Factorunlistedcustomer

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

Price

rebased to 0%

ERNA, solidLLY, dashed